Acumen Pharmaceuticals has confirmed that sabirnetug (ACU193), a humanised monoclonal antibody (mAb) selective for toxic soluble amyloid-beta (Aβ) oligomers, failed to meet the primary endpoint in the Phase II ALTITUDE-AD study in early Alzheimer's disease (AD).
The 542-patient randomised trial tested 35 mg/kg and 50 mg/kg doses every four weeks against placebo, with the integrated AD Rating Scale change at 18 months as the key measure; neither dose separated from placebo, key secondary endpoints including CDR-SB were also missed, and although PET imaging showed statistically significant plaque reduction at week 36 and week 76, cognitive and functional decline was not slowed.
The result is a setback for the soluble-oligomer hypothesis as a standalone therapeutic strategy, even though sabirnetug was generally tolerable aside from amyloid-related imaging abnormalities-oedema in about 10% of treated subjects. Acumen will analyse remaining biomarker and imaging data but does not expect the efficacy conclusion to change, and has opted to terminate development including the open-label extension while preserving cash and reviewing strategic options around its Enhanced Brain Delivery platform.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation